TEL AVIV, Israel, March 2, 2022 /PRNewswire/ -- Chemomab
Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage
biotechnology company focused on the discovery and development of
innovative therapeutics for fibrotic and inflammatory diseases with
high unmet need, today announced the company will release its
fourth quarter and full year 2021 financial results and provide a
business update on Wednesday, March 9,
2022. The company will host a conference call and
webcast at 8:00 a.m. Eastern Time on
the same day, which will be broadcast live at the link below and on
the company's investor relations website at
investors.chemomab.com/events. The conference call will also be
available by telephone.
During the conference call, Chemomab's management team will
review fourth quarter and full year 2021 performance, discuss
recent and upcoming events and conduct a question-and-answer
session.
Conference Call and Webcast Information:
Live Webcast at 8:00 am Eastern
Time, March 9, 2022
Click this Webcast link to access the live webcast or
replay.
The live webcast and replay can also be accessed at the News
& Events section of the Investors page on
the Chemomab website
at investors.chemomab.com/events.
By Telephone
Conference call information:
US Investors:
+1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference ID: 13727097
Please call 5-10 minutes before the scheduled start time and ask
for the Chemomab conference call.
About Chemomab Therapeutics
Chemomab is a clinical-stage biotechnology company focusing on
the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in two Phase 2 safety and efficacy trials—one in patients
with primary sclerosing cholangitis and the second in patients with
liver fibrosis, with a third Phase 2 trial in systemic sclerosis
expected to begin in early 2022. For more information on Chemomab,
visit chemomab.com.
Contacts:
Investor
Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1 (917) 734-7387
ir@chemomab.com
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations,
Strategic Communications
Phone: +1 (917) 355-9234
barbara@chemomab.com
Logo -
https://mma.prnewswire.com/media/1315158/Chemomab_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-and-provide-a-business-update-301493870.html
SOURCE Chemomab Therapeutics Ltd